Original Research Article
Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s DiseaseEriksdotter-Jönhagen M.a, d · Linderoth B.b, e · Lind G.b, e · Aladellie L.f · Almkvist O.a, i · Andreasen N.a, d · Blennow K.j · Bogdanovic N.a · Jelic V.a, d · Kadir A.a · Nordberg A.a, d · Sundström E.a, h · Wahlund L.-O.a, d · Wall A.k · Wiberg M.c, g · Winblad B.a, d · Seiger Å.a, d, h · Almqvist P.b, e, l · Wahlberg L.a, l
Departments of aNeurobiology, Caring Sciences and Society, bClinical Neuroscience and cClinical Science, Karolinska Institutet, Departments of dGeriatrics, eNeurosurgery, fEmergency Medicine and gRadiology, Karolinska University Hospital, hStockholms sjukhem, and iDepartment of Psychology, Stockholm University, Stockholm, jDepartment of Clinical Neuroscience, Clinical Neurochemistry Laboratory, University of Göteborg, Göteborg, and kDepartment of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden; lNsGene A/S, Ballerup, Denmark
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aims: Degeneration of cholinergic neurons in the basal forebrain correlates with cognitive decline in patients with Alzheimer’s disease (AD). Targeted delivery of exogenous nerve growth factor (NGF) has emerged as a potential AD therapy due to its regenerative effects on the basal forebrain cholinergic neurons in AD animal models. Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability. Methods: This was an open-label, 12-month study in 6 AD patients. Patients were implanted stereotactically with EC-NGF biodelivery devices targeting the basal forebrain. Patients were monitored with respect to safety, tolerability, disease progression and implant functionality. Results: All patients were implanted successfully with bilateral single or double implants without complications or signs of toxicity. No adverse events were related to NGF or the device. All patients completed the study, including removal of implants at 12 months. Positive findings in cognition, EEG and nicotinic receptor binding in 2 of 6 patients were detected. Conclusions: This study demonstrates that surgical implantation and removal of EC-NGF biodelivery to the basal forebrain in AD patients is safe, well tolerated and feasible.
© 2012 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.